Translating 5‐HT4 receptor pharmacology

  title={Translating 5‐HT4 receptor pharmacology},
  author={Gareth John Sanger},
  journal={Neurogastroenterology \& Motility},
  • G. Sanger
  • Published 1 December 2009
  • Biology
  • Neurogastroenterology & Motility
Abstract  Since metoclopramide was first described (in 1964) there have been several attempts to develop compounds which retained gastrointestinal prokinetic activity (via 5‐HT4 receptor activation) but without the limiting side effects associated with dopamine D2 receptor antagonism. Early compounds (mosapride, cisapride, renzapride, tegaserod) were identified before several of the 5‐HT receptors were even described (including 5‐HT4 and 5‐HT2B), whereas prucalopride came later. Several… 

The Pharmacology of TD-8954, a Potent and Selective 5-HT4 Receptor Agonist with Gastrointestinal Prokinetic Properties

It is concluded that TD-8954 is a potent and selective 5-HT4 receptor agonist in vitro, with robust in vivo stimulatory activity in the gastrointestinal (GI) tract of guinea pigs, rats, dogs, and humans and may have clinical utility in patients with disorders of reduced GI motility.

Constipation, IBs and the 5-HT4 Receptor: What Role for Prucalopride?

Prucalopride is now the first of a new class of drug defined by selectivity and high intrinsic activity at the 5-HT4 receptor, characterized by good selectivity at the5-HT 4 receptor, high intrinsicactivity and efficacy in patients with chronic constipation.

Metoclopramide : A Template for Drug Discovery

The serendipitous discovery of this drug has contributed to development of three new drug classes: selective (peripherally-restricted) antagonists at D2 and 5- HT3 receptors and selective agonists at the 5-HT4 receptor, used to treat idiopathic constipation.

New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders

Prucalopride, ATI-7505, and velusetrag are highly selective, high-affinity 5-HT4 receptor agonists that are devoid of action on other receptors within their therapeutic range that are promising approaches to treat GI dysmotility, particularly colonic diseases.

Serotonin receptors nomenclature

Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility

Both the AChE inhibitor donepezil and prucalopride, the first selective, clinically available 5‐HT4 receptor agonist, were examined for their individual and potential synergistic activities in human colon.

A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model

Results indicate that MCP-azo-ASA is a colon-specific prodrug of MCP, and targeted delivery of M CP to the colon ameliorated DNBS-induced colitis in rats, and the ability of MDP to target the colon in vitro and in vivo was evaluated.

Emerging drugs for functional dyspepsia

While many new prokinetic drugs are in the early stages of evaluation, acotiamide emerges as the drug with a promising efficacy profile, especially for postprandial distress syndrome.



5‐HT4 receptor agonists: similar but not the same

The concept of ligand‐directed signalling offers great opportunities for future drug development by enlarging the scientific basis for the generation of agonist‐specific effects in different cell types, tissues or organs.

The in vitro pharmacological profile of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity

The high intrinsic activity and preferential binding of TD-5108 to 5- HT4 over other 5-HT receptors may result in an improved clinical profile for the treatment of gastrointestinal disorders of reduced motility.

The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists.

A number of substituted indole carbazimidamides were prepared and evaluated as 5-HT4 receptor agonists by using the isolated field-stimulated guinea pig ileum preparation and several selective and highly potent full as well as partial agonists emerged.

Differential Effects of 5-Hydroxytryptamine4 Receptor Agonists at Gastric versus Cardiac Receptors: An Operational Framework to Explain and Quantify Organ-Specific Behavior

In vitro studies of gastric and cardiac effects of 5-HT4 receptor ligands in the pig indicate that these interactions do not follow a simple competitive pattern and that they differ between stomach and left atrium.

Pharmacological characterization of the human 5‐HT4(d) receptor splice variant stably expressed in Chinese hamster ovary cells

It is concluded that C‐terminal tails of 5‐HT4 receptor isoforms may directly influence their functional properties.

5‐HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle

  • S. CellekA. K. John G. Sanger
  • Biology
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2006
In the circular muscle of human colon, 5‐HT4 receptor agonists simultaneously facilitate the activity of neurones which release the inhibitory and excitatory neurotransmitters, nitric oxide and acetylcholine respectively.

Serotonin pharmacology in the gastrointestinal tract: a review

Advances in understanding of the physiological and pathophysiological roles of 5-HT in the ENS and the identification of selective receptor ligands bodes well for the future development of more efficacious therapies for patients with functional GI disorders.

Human 5–HT4 and 5–HT7 Receptor Splice Variants: Are they Important?

This review examines the functional relevance and known and candidate signalling systems that allow for splice variant specific responses include GPCR interacting proteins (GIPs) and G PCR receptor kinases (GRKs) which are examined.

Inhibition of colonic motility and defecation by RS‐127445 suggests an involvement of the 5‐HT2B receptor in rodent large bowel physiology

The 5‐HT2B receptor antagonist RS‐127445 was characterized and its effects on peristalsis and defecation were studied to explore the role of these receptors.